These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10657408)

  • 1. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience.
    Tanne D; Gorman MJ; Bates VE; Kasner SE; Scott P; Verro P; Binder JR; Dayno JM; Schultz LR; Levine SR
    Stroke; 2000 Feb; 31(2):370-5. PubMed ID: 10657408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Tissue Plasminogen Activator in Stroke Mimics.
    Ali-Ahmed F; Federspiel JJ; Liang L; Xu H; Sevilis T; Hernandez AF; Kosinski AS; Prvu Bettger J; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005609. PubMed ID: 31412730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours.
    Röther J; Schellinger PD; Gass A; Siebler M; Villringer A; Fiebach JB; Fiehler J; Jansen O; Kucinski T; Schoder V; Szabo K; Junge-Hülsing GJ; Hennerici M; Zeumer H; Sartor K; Weiller C; Hacke W;
    Stroke; 2002 Oct; 33(10):2438-45. PubMed ID: 12364735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
    Shah S; Liang L; Kosinski A; Hernandez AF; Schwamm LH; Smith EE; Fonarow GC; Bhatt DL; Feng W; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006031. PubMed ID: 31903770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients.
    Berrouschot J; Röther J; Glahn J; Kucinski T; Fiehler J; Thomalla G
    Stroke; 2005 Nov; 36(11):2421-5. PubMed ID: 16210554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
    Chalela JA; Kasner SE; Jauch EC; Pancioli AM
    Stroke; 1999 Nov; 30(11):2366-8. PubMed ID: 10548672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
    Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
    Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
    Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA
    JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older.
    Mateen FJ; Nasser M; Spencer BR; Freeman WD; Shuaib A; Demaerschalk BM; Wijdicks EF
    Mayo Clin Proc; 2009 Apr; 84(4):334-8. PubMed ID: 19339651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
    Saver JL; Fonarow GC; Smith EE; Reeves MJ; Grau-Sepulveda MV; Pan W; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2013 Jun; 309(23):2480-8. PubMed ID: 23780461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.
    Merkler AE; Salehi Omran S; Gialdini G; Lerario MP; Yaghi S; Elkind MSV; Navi BB
    Stroke; 2017 Aug; 48(8):2282-2284. PubMed ID: 28679847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.